Beacon's gene therapy data in rare eye disease Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 21 September, 2026

The Endpoints 11 revealed live at the State Room in Boston, plus a fireside chat with the Wyss Institute's Don Ingber and an evening with the founders, scientists and investors behind the list. Reserve your spot with code ELEVEN26. Can't get to Boston? Join us virtually, free.

presented by Every­body op­ti­mizes the first 20% of pa­tient re­cruit­ment. Tri­als fall apart in the oth­er 80%.

news Novo aims to diversify with new pipeline assets and bolt-on deals Beacon says gene therapy succeeds in key trial of rare eye disease XLRP Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial FDA approves Lilly's oral SERD combo for second-line breast cancer therapy All 50 states sign up for most favored nation prices under Medicaid, Trump says

Sep 22 12:00 pm ET The future of drug pricing: Medicare negotiation, MFN models & beyond sponsored by ADVI Oct 13 11:00 am ET Commercial excellence and AI - a ripple, wave or a tsunami sponsored by ZS Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

Vice President, Regulatory Affairs Hinge Bio, Inc. Redwood City, CA, USA Team Leader, Analytical Research & Development (ARD) Veranova Devens, MA 01434, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

The entire healthcare ecosystem is more Silicon Valley-ified than ever before. What tech has actually changed? Is biopharma behind? Find out, join us for Health Tech day.

ENDPOINTS PHARMA China sets ambitious goals for global drug and biotech expansion in new five-year plan •  Post-Hoc Live: The China Biotech Debate goes to Washington CHMP backs Novo’s hemophilia A drug and seven other medicines  FDA says initial rejections of new drugs have declined

in case you missed it 1. Updated: Electra says $350M IPO will help it become a commercial biotech